The Gist Healthcare Podcast Friday, November 7, 2025
Nov 7, 2025
Discover significant developments in healthcare, from the Trump administration's major price cuts on GLP-1 weight loss drugs to the FDA's efforts in streamlining biosimilar drug approval. Learn about UnitedHealthcare's higher payment rates for Optum physicians and the ongoing debate this has sparked. Additionally, hear insights on improving surgical patient safety from experts. Stay informed on these pivotal issues shaping the healthcare landscape!
AI Snips
Chapters
Transcript
Episode notes
Major Price Cuts For GLP-1 Drugs
- The Trump administration struck deals to cut GLP-1 weight-loss drug list prices dramatically for its TrumpRx platform launching in early 2026.
- Medicare and Medicaid coverage will expand for weight management with reduced manufacturer and Medicare prices taking effect mid-2026.
FDA Moves To Accelerate Biosimilars
- The FDA issued guidance to simplify biosimilar development and remove unnecessary testing to speed market entry and interchangeability with brand biologics.
- Biologics are a small share of prescriptions but drove about half of 2024 drug spending, so easier biosimilar pathways aim to lower costs.
Act Now On FDA Draft Guidance
- Review and submit public comments on the FDA's draft guidance within the 60-day Federal Register window to influence biosimilar rules.
- Engage stakeholders quickly because the guidance shapes interchangeability and testing requirements.